Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.46 |
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 13/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050743 | 0.94 | BDKRB1 (0.43) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL3143255 | 0.93 | DRD2 (0.47) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL3149321 | 0.90 | KMT2A (0.47) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL15103931 | 0.87 | CCR2 (0.39) | — | |
| SCHEMBL3148946 | 0.86 | BDKRB1 (0.44) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL3143699 | 0.86 | DRD2 (0.47) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL3153187 | 0.85 | CA12 (0.50) | DRD2 | |
| SCHEMBL3052623 | 0.85 | BDKRB1 (0.41) | DRD3DRD2HTR2ABDKRB1 | |
| SCHEMBL3149102 | 0.85 | DRD2 (0.51) | DRD3DRD2HTR2A | |
| SCHEMBL3140709 | 0.84 | NAMPT (0.47) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | claimed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | claimed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | DRD3 467/4885DRD2 424/4885HTR2A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.